An Observational Clinical Study to Evaluate the Efficacy of the CeraVe Skin Care Line

Inclusion criteria

• Chinese males and females, age eligible greater than or equal to 13 years old;
• Be in good health and free from any other chronic disease or disease under treatment;
• Be judged by a dermatologist at the Baseline visit:

Mild, moderate, or severe acne according to the Global Evaluation Acne Grading Scale (GEA)11,12 (Mild - Grade 1 or Grade 2) Acne Grading Scale (GEA) - Scale 1 or 2, Moderate - Scale 3, Severe - Scale 4 or above);

• Initiation of acne treatment within the last 3 months with medications that include, but are not limited to, the following

• Topical medications: benzoyl peroxide (BPO), retinoic acid, adapalene, isotretinoin, azelaic acid, 0.1% adapalene/BPO. b) Topical medications: benzoyl peroxide (BPO), retinoic acid, adapalene, isotretinoin, azelaic acid, adapalene 0.3% adapalene/BPO, retinoic acid/clindamycin, BPO/clindamycin;
• Oral medications: antibiotics, spironolactone, isotretinoin, etc; If Global Evaluation Acne Grading Scale (GEA) classification is ≥2, continuous use of the above medications for at least 2 weeks prior to the baseline visit is required.

If the Global Evaluation Acne Grading Scale (GEA) is ≥2, acne treatment with the above medications should be continued for at least 2 weeks before the baseline visit; If oral medication is used, acne treatment should be continued for at least 4 weeks prior to the baseline visit.

Exclusion criteria

• Adult female study participants who intend to plan a pregnancy, or who are pregnant, breastfeeding, within 6 months of delivery, or who are unwilling to take the necessary precautions to avoid pregnancy;
• Study participants who are currently enrolled in another clinical study or have been enrolled in another clinical study within 3 months;
• Study participants who have undergone physical, chemical, or cosmetic surgery within 3 months prior to enrollment;
• Systemic diseases with severe organ damage, cardiovascular diseases, liver or kidney dysfunction, malignant tumors, chronic diseases with unstable control, acute infectious diseases, major surgeries or traumas, psychological and psychiatric disorders, or other diseases that require topical or systemic use of medications or treatments that have an effect on acne;
• The study site is associated with other skin disorders (atopic dermatitis, rosacea, rosacea, eczema, etc.) or the presence of other skin conditions that interfere with evaluation (birthmarks, scarring, etc.);
• Participants in the study have a history of allergic contact dermatitis caused by cleansers (facial cleansers)/moisturizers;
• History of allergy or severe allergy to the products (Sensitive Skin products) and related ingredients provided in the study;
• Study participants who are unable to follow compliance requirements, or who are known to be unable to attend visits on time, or who are unwilling to comply with the study protocol arrangements for the duration of the study;
• Any clinical presentation or other illness in the required observation area that, in the opinion of the investigator, may affect the study product assessment or results.
• Study participants had received medical aesthetic treatments (including but not limited to photofacial type treatments, fruit acid resurfacing, etc.) within 3 months prior to enrollment.